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Abstract 
Greater than 80% of malaria-related mortality occurs in sub-Saharan Africa due to infections 
with Plasmodium falciparum. The majority of P. falciparum-related mortality occurs in im-
mune-naïve infants and young children, accounting for 18% of all deaths before five years of 
age. Clinical manifestations of severe falciparum malaria vary according to transmission in-
tensity and typically present as one or more life-threatening complications, including: hy-
perparasitemia; hypoglycemia; cerebral malaria; severe malarial anemia (SMA); and respira-
tory distress. In holoendemic transmission areas, SMA is the primary clinical manifestation of 
severe childhood malaria, with cerebral malaria occurring only in rare cases. Mortality rates 
from SMA can exceed 30% in pediatric populations residing in holoendemic transmission 
areas. Since the vast majority of the morbidity and mortality occurs in immune-naïve African 
children less than five years of age, with SMA as the primary manifestation of severe disease, 
this  review  will  focus  primarily on  the  innate  immune  mechanisms  that  govern  malaria 
pathogenesis in this group of individuals. The pathophysiological processes that contribute to 
SMA involve direct and indirect destruction of parasitized and non-parasitized red blood cells 
(RBCs), inefficient and/or suppression of erythropoiesis, and dyserythropoiesis. While all of 
these causal etiologies may contribute to reduced hemoglobin (Hb) concentrations in ma-
laria-infected  individuals, data  from our  laboratory and  others  suggest  that  SMA  in  im-
mune-naïve children is characterized by a reduced erythropoietic response. One important 
cause of impaired erythroid responses in children with SMA is dysregulation in the innate 
immune response. Phagocytosis of malarial pigment hemozoin (Hz) by monocytes, macro-
phages, and neutrophils is a central factor for promoting dysregulation in innate inflammatory 
mediators. As such, the role of P. falciparum-derived Hz (PfHz) in mediating suppression of 
erythropoiesis through its ability to cause dysregulation in pro- and anti-inflammatory cyto-
kines, growth factors, chemokines, and effector molecules is discussed in detail. An improved 
understanding of the etiological basis of suppression of erythropoietic responses in children 
with SMA may offer the much needed therapeutic alternatives for control of this global 
disease burden. 
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1. Human Malaria 
Human malaria is caused by unicellular obligate 
intracellular protozoan parasites of the genus Plasmo-
dium.  Although  malaria  was  once  prevalent 
throughout  most  of  the  world,  malaria  is  currently 
endemic in the tropical zones with extensions into the 
sub-tropical regions of Asia, Africa, South and Central 
America. However, about half of the world‘s popula-
tion (3.3 billion people) is at risk of malaria in more 
than 100 countries [1]. Four primary species of malaria 
parasites infect humans: P. falciparum, P. ovale, P. ma-
lariae and P. vivax. In addition, studies in Southeast 
Asia have shown that P. knowlesi, a malaria parasite 
that typically involves monkeys as the natural reser-
voir, can also infect humans, and in some cases, result 
in fatal disease (reviewed in  [2]). Malaria due to P. 
vivax, P. ovale and P. malariae is less severe than that 
experienced  by  P.  falciparum  infections  and  collec-
tively, these three species account for slightly less than 
10%  of  the  worldwide  malaria  cases  [3].  The  most 
virulent of the human malaria parasites is P. falcipa-
rum which is responsible for the bulk of the malar-
ia-related  morbidity  and  mortality.  P. falciparum  ac-
counts for 91% of malaria cases worldwide of which 
the majority (i.e., 86%) occurs in the African region [3]. 
Consistent with the high rate of morbidity within Af-
rica,  90%  of  the  P.  falciparum-attributable  malaria 
deaths  also  occur  in  the  African  region,  primarily 
sub-Saharan  Africa  [3].  Approximately  247  million 
malaria infections are estimated annually, resulting in 
greater than one million deaths, primarily in African 
children under the age of five [1].  
2. Clinical Spectrum of Plasmodium falci-
parum Infections 
The clinical spectrum of P. falciparum malaria in 
African children encompasses a wide range of path-
ophysiological  derangements  and  includes  multiple 
organ  involvement  and  systemic  disorders.  Falcipa-
rum malaria ranges from asymptomatic infections to 
the  classic  symptoms  of  malaria  (e.g.,  fever,  chills, 
sweating,  headache  and  muscle  aches),  which  in  a 
sub-population  of  the  cases,  results  in  severe 
life-threatening  complications  such  as  hyperpara-
sitemia, hypoglycemia, hyperlactatemia, kidney fail-
ure, metabolic acidosis, cerebral malaria, severe ma-
larial anemia [SMA, hemoglobin, (Hb)<5.0 g/dL], and 
respiratory distress (RD) [4, 5]. Although the patho-
physiology of malaria is multifactorial and only par-
tially understood, development of a pathogenic ver-
sus protective outcome, once an infection occurs, is 
mediated by host and parasite interactions of which 
the following appear critically important: endemicity 
patterns,  acquisition  of  naturally  acquired  malarial 
immunity, parasite virulence, multiplication rate, an-
tigenic variation and polymorphic variability in both 
the host (human) and parasite [6]. The age of the in-
dividual when they first acquire a malarial infection 
also plays a significant role in the clinical outcomes of 
the  disease  process.  For  example,  children  typically 
display enhanced susceptibility to severe anemia and 
hypoglycemia,  while  non-resident  malaria-naïve 
adults are more likely to present with jaundice and 
progress to renal failure and respiratory distress due 
to pulmonary edema [7].  
3. Infant and Childhood Anemia in De-
veloping Nations 
Although  this  review  will  focus  primarily  on 
SMA and the innate immune responses that condition 
the  development  and  outcomes  of  the  disease,  it  is 
important  to  understand  the  definitions  of  anemia 
and the importance of geographic context. A general 
definition of anemia is a reduction in Hb levels in re-
lation to the age, gender, and physiological status of 
the individual within a defined geographical context 
[8]. In western countries, anemia is defined by a Hb 
concentration <12.0 g/dL, while in developing coun-
tries the standard definition of anemia for children <5 
years of age is Hb<11.0 g/dL [8]. Throughout much of 
the  developing  world,  particularly  in  regions  of 
sub-Saharan  Africa  with  high  rates  of  malaria  and 
human immunodeficiency virus (HIV), the majority of 
infants  and  young  children  suffer  from  anemia  [9]. 
Anemia in the developing world is largely a product 
of  inadequate  feeding  practices,  frequent  infections, 
and  micronutrient  deficiencies  which  culminate  in 
high rates of mortality in infants and young children 
[9].  
4. Disease Burden of Severe Malarial Ane-
mia 
The World Health Organization (WHO) defines 
SMA as Hb concentrations <5.0 g/dL (or a hematocrit 
<15.0%) in the presence of any density parasitemia [5]. 
SMA is a major public health problem in developing 
countries where it contributes 3-46% of inpatient pe-
diatric fatalities in referral care facilities [10]. Despite 
efforts  aimed  at  ameliorating  the  anemia  burden, 
SMA remains an important childhood health burden 
in  sub-Saharan  Africa  [11].  Previous  studies  in  en-
demic areas of Africa demonstrated that the annual 
rate  of  presentation  to  hospital  with  SMA  was 
7.6/1000 in children aged 0-4 years with a case fatality 
of 9.7% [12]. Additional studies illustrate that the risk 




transmission regions and at approximately 2 years of 
age in areas with moderate and low transmission in-
tensities, such that (in general) the overall risk of SMA 
decreases with increasing age [13]. Multicentre stud-
ies indicate that SMA affects 7.5-34% of the African 
children that acquire malaria with an overall preva-
lence of 21.2% and case fatality rate of 8.4% [14].  
5. Etiological Basis of Severe Malarial 
Anemia 
The etiology  of SMA can include a number of 
distinct,  as  well  as  overlapping  features,  including 
lysis of infected and uninfected RBCs [15-18], splenic 
sequestration  of  RBCs  [19],  dyserythropoiesis  and 
bone marrow suppression [20, 21], co-infections with 
bacteremia,  HIV-1,  and  hookworm  [22-26],  and 
chronic  transmission  of  malaria  in  holoendemic  re-
gions. It is important to note that some or all of these 
factors can culminate in the chronically low Hb values 
observed  in  infants  and  young  children  residing  in 
holoendemic  regions.  As  such,  the  degree  of  para-
sitemia is typically a poor indicator of malaria disease 
severity  in  these  locales,  especially  considering  that 
peripheral parasitemia is a ―snapshot‖ in time of the 
complex and continuously evolving disease process. 
However, it is important to stress that high levels of 
parasitemia, particularly in non-immune individuals, 
can certainly result in massive lysis and clearance of 
RBCs, resulting in profound anemia [21, 27]. 
6. Impaired Erythropoietic Responses in 
Severe Malarial Anemia 
Although  parasite-driven  hemolysis  will  con-
tribute to a reduction in Hb levels in childhood ma-
laria, one of the primary mechanisms responsible for 
low  Hb  levels  in  children  with  SMA  is  impaired 
and/or ineffective erythropoiesis. Loss of appropriate 
production of erythrocytes translates into a failure in 
the ability to replenish the reduced pool of erythro-
cytes  due  to  parasite-  and/or  anti-malarial-driven 
hemolysis. Earlier studies demonstrated that there is 
parenchymal  damage  of  bone  marrow,  ineffective 
erythropoiesis, and a reduced rate of erythropoietic 
proliferation  in  patients  with  acute  falciparum  ma-
laria  [28].  Subsequent  studies  in  Gambian  children 
demonstrated  that  SMA  was  defined  by  erythroid 
hyperplasia with dyserythropoiesis [6]. Examination 
of  bone  marrow  from  children  with  SMA  revealed 
hypercellularity,  mild  to  normal  erythroid  hyper-
plasia, and abnormal features of late erythroid pro-
genitors,  but  absence  of  damage  to  burst  forming 
unit-erythrocyte  (BFU-E)  or  colony  forming 
unit-erythrocyte (CFU-E) early stages [6]. In addition, 
we have shown that children with SMA have an inef-
ficient reticulocyte production index (RPI) character-
ized by levels <2.0 [29]. The RPI is a measure of the 
extent to  which the reticulocyte count has risen (or 
not)  in  response  to  the  level  of  anemia  [30].  Taken 
together, these  investigations demonstrate that sup-
pression of erythropoiesis is a primary cause of severe 
anemia in children with P. falciparum infections.  
7. Role of Inflammatory Mediators in Im-
paired Erythropoiesis 
Although  the  precise  mechanisms  responsible 
for  reduced  reticulocyte  responses  in  children  with 
SMA have been somewhat elusive, it is clear that one 
important cause of reduced erythropoiesis in children 
with  SMA  is  due  to  an  imbalance  in  inflammatory 
mediators. In an attempt to control the parasitemia, 
the  host  releases  an  array  of  pro-  and  an-
ti-inflammatory  cytokines,  chemokines,  growth  fac-
tors, and effector molecules as part of the innate im-
mune  response.  Depending  on  the  magnitude  and 
timing of inflammatory mediator release, the immune 
response  to  malaria  can  result  in  either  successful 
control  of  the  parasitemia  or  alternatively,  an  inap-
propriate balance in the inflammatory milieu that can 
induce damage to the host, including suppression of 
the  erythropoietic  response.  As  such,  although  ma-
laria is typically viewed as an ‗acute‘ infection, in re-
gions with high levels of falciparum endemicity, SMA 
is often a more ‗chronic‘ condition in which the im-
munological response to infection drives an inflam-
matory  milieu  that  can  promote  suppression  of  ey-
thropoiesis.  This  premise  is  supported  by  observa-
tions showing that persistent childhood P. falciparum 
infections are associated with bone marrow suppres-
sion [31].  
8. Role of Parasitic Products in Stimulating 
the Innate Immune Response 
There  are  a  number  of  key  parasitic  products 
that drive the innate immune response in the malar-
ia-infected  human  host,  including  malarial  pigment 
(hemozoin,  Hz),  glycosylphosphatidylinositols 
(GPIs), and parasitic antigens. While it is clear that 
GPIs, which form the connection between the para-
site‘s cellular membrane and external antigens [32], as 
well  as  an  array  of  parasitic  antigens  play  an  im-
portant role in activating the immune response, we 
will  focus  our  discussion  on  the  role  of  P.  falcipa-
rum-derived Hz (PfHz) in promoting the host immune 
response and the potential implications that this pro-
cess  has  on  suppression  of  the  erythropoietic  re-




parasite GPIs [33] and malarial antigens stimulate the 
innate immune response can be found elsewhere [34].  
9. Hemozoin Formation 
The importance of hemozoin in malarial infec-
tions was recognized over five decades ago following 
the  discovery  that  accumulation  of  phagocytosed 
malarial  pigment  in  bone  marrow  produces  a 
brown/black  appearance  in  patients  with  repeated 
malaria  infections  [35].  Formation  of  PfHz  occurs 
during the intraerythrocytic asexual replication cycle 
in which P. falciparum metabolizes host Hb as a source 
of  amino  acids  [36,  37],  leaving  the  iron-rich  heme 
portion designated ferriprotoporphyrin IX (FP-IX). P. 
falciparum  then  promotes  aggregation  of  the  toxic 
FP-IX molecules, using heme polymerase [38, 39], into 
an insoluble product known as PfHz [40-42]. Once the 
schizont has gone through replication within the host 
RBC,  the  erythrocyte  ruptures  [43],  releasing  PfHz 
along with merozoites, with the newly-formed mer-
ozoites infecting other RBCs, and PfHz being phago-
cytosed by monocytes/macrophages and neutrophils.  
10. Hemozoin Accumulation as a Causal 
Factor in Suppression of Erythropoiesis 
Accumulation of phagocytes containing malaria 
pigment in the microvasculature of deep tissues such 
as the bone marrows of patients with acute malaria 
was recognized in earlier studies [44]. Intraleukocytic 
malaria pigment is a useful direct diagnostic marker 
with  the  amount  of  phagocytosed  pigment  being  a 
good  indirect  measure  of  the  sequestered  parasite 
burden, recent schizogony, and disease severity [45]. 
Studies by others and our group have also found an 
association between the presence of PfHz-containing 
monocytes and suppression of erythropoiesis in chil-
dren with P. falciparum-induced anemia [46, 47]. In 
addition, our studies in western Kenya, using multi-
variate regression analyses, controlling for age, gen-
der, and parasitemia, revealed that elevated levels of 
pigment-containing monocytes (PCM) were a signif-
icant predictor of SMA [47]. A recent multi-site study 
that  included  26,296  hospitalized  children  with  P. 
falciparum malaria demonstrated that the percentage 
of PfHz-containing monocytes was negatively corre-
lated with hematocrit [48]. Additional evidence that 
PfHz-containing  cells  are  an  important  source  for 
promoting  erythroid  suppression  is  supported  by 
histological observations of bone marrow in children 
with SMA, and those dying from  malaria, showing 
that developing erythroid progenitors located within 
the vicinity of pigmented macrophages have abnor-
mal cellular development [46]. Consistent with these 
observations, we recently demonstrated that elevated 
levels of PfHz in monocytes are associated with inef-
ficient erythropoiesis in Kenyan children with malaria 
[49].  
11. Severe Malarial Anemia is Character-
ized by Dysregulation in Innate Inflam-
matory Mediators 
One  of  the  primary  factors  for  stimulating  the 
innate immune response to P. falciparum is phagocy-
tosis  of  PfHz  by  circulating  monocytes  and  neutro-
phils, and resident macrophages. One of the primary 
means  by  which  PfHz  generates  an  innate  immune 
response is through the toll-like receptors (TLRs). A 
recent  review  discussing  the  role  of  hemozoin  in 
stimulating the TLRs can be found elsewhere [50]. The 
studies  discussed  below  support  a  model  in  which 
phagocytosis of PfHz, and the host immune response 
patterns that ensue following this event, are a critical 
step  in  the  promotion  of  the  reduced  erythroid  re-
sponses  observed  in  children  with  SMA  (Figure  1). 
Although it is clear that a wealth of important cellular 
biology is yet to be elucidated about the mechanisms 
by  which  phagocytosis  of  PfHz  shapes  the  innate 
immune response, the ability of PfHz to alter inflam-
matory  mediator  profiles  is  central  to  its  action. 
However, it is important to note that clarification of 
strict protective versus pathological roles for inflam-
matory  mediators  remains  poorly  defined  and  ex-
tremely  difficult  to  quantify  in  human  malaria  in 
which manipulation of the biological systems is typi-
cally not feasible.  
Pro-inflammatory Mediators 
A successful type 1 response to malaria requires 
a well-timed and proportional release of interleukin 
(IL)-12, interferon (IFN)-γ, and tumor necrosis factor 
(TNF)-α  to  minimize  parasitemia  and  preserve 
erythropoiesis [51, 52]. The pro-inflammatory phase 
should be followed by an equally timely abrogation of 
this  response  by  type  2  cytokines  such  as  IL-10, 
transforming  growth  factor  (TGF)-β,  and  IL-4,  to 
avoid inflammatory host damage [53]. 
TNF-α is the molecule typically associated with 
pathology in malaria and was first hypothesized to be 
involved in the host immune response to malaria in 
1978 [54]. Several studies have shown an association 
between  elevated  TNF-α  levels  and  morbidity  and 
mortality in individuals with malaria [55, 56]. How-
ever,  TNF-α  is  critical  for  parasite  killing  and  pre-
venting parasite replication [55-59]. In addition to its 
direct effects [60, 61], TNF-α also mediates its effects 
by  inducing  production  of  macrophage  migration 
inhibitory factor (MIF) [62, 63] and nitric oxide syn-




iNOS) [64], which through generation of nitric oxide 
(NO)  also  has  direct  parasite  killing  effects  [65]. 
TNF-α can also exacerbate inflammation by inducing 
cyclooxygenase (COX)-2 and subsequently generated 
effector molecules, such as prostaglandins [66]. Many 
of the signs and symptoms associated with malaria, 
such as fever, headache, nausea, vomiting, diarrhea, 
anorexia,  myalgias,  and  thrombocytopenia  can  be 





Figure 1. Proposed Model of Dysregulation in Innate Immune Responses in Severe Malarial Anemia. Based on 
concomitant measurement of innate inflammatory mediators (using multiplex technologies) in children with varying se-
verities of malarial anemia, we developed a model to describe how dysregulation in innate inflammatory mediators promotes 
suppression of erythropoiesis in children with SMA. Central to the model is the fact that phagocytosis of hemozoin (PfHz) 
by monocytes is one of the primary causes of altered production of innate inflammatory mediators. Elevated inflammatory 
mediators are shown in green text, while those that are decreased in children with SMA are shown in red text. Solid lines 
indicate positive signaling (up-regulation), whereas dashed lines indicate suppression (down-regulation). Children with SMA 
have decreased levels of IL-12 in response to ingestion of parasitized red blood cells (pRBC) and/or hemozoin by monocytes. 
Suppression of IL-12 in children with SMA is due to PfHz-induced IL-10 over-production. Children with SMA have increased 
circulating levels of TNF-α, IFN-γ, IL-6, MIP-1α, and MIP-1β. Although TNF-α can induce PGE2 and nitric oxide (NO), these 
effector molecules are suppressed in children with SMA. Suppression of PGE2 allows over-production of TNF-α, which is 
associated with enhanced severity of anemia. In addition, MIF is suppressed in children with falciparum malaria, an event 
associated with phagocytosis of PfHz by monocytes, and enhanced severity of anemia. Circulating levels of IFN-α, IL-1β, 
RANTES, and SCGF are also decreased in children with SMA. Reduced production of these innate inflammatory mediators, 
along with increased TNF-αIL-6, MIP-1α and MIP-β, likely contribute to the development of SMA by suppressing the 
erythropoietic response. Lastly, although the reduced NO and reactive oxygen species (ROS) generation reported in 
children with falciparum malaria may promote ineffective parasite killing and, thereby, prolong parasitemia, children with 
malarial anemia have elevated levels of NO and ROS that can directly inhibit erythropoiesis. 
 





IFN-γ  is  produced  by  natural  killer  and  αβ-T 
cells, as well as the regulatory γδ-T cells, during the 
early  phases  of  the  immune  response  to  a  malaria 
infection [68-70]. This prototypical type 1 cytokine is a 
key  molecule  for  protecting  against  infection  in 
childhood malaria [71] and in non-immune volunteers 
experimentally infected with malaria [72]. The ability 
to generate IFN-γ from mononuclear cells exposed to 
asexual malaria parasites has recently been attributed 
to the significant resistance to P. falciparum malaria in 
the Fulani people of West Africa compared to other 
tribes in the Mali, Burkina Faso, and Sudan regions 
[73].  Consistent  with  a  protective  role,  IFN-γ  re-
sponses to CD8+ T cell epitopes from pre-erythrocytic 
antigens  are  associated  with  higher  Hb  levels,  and 
reduced prevalence of SMA in Kenyan children [74]. 
Although both TNF-α and IFN-γ appear to play 
a  protective  role  in  children  and  adults  during  the 
early stages of a P. falciparum infection through their 
ability to stimulate monocyte/macrophage activation 
and  aid  in  controlling  parasitemia  [75], 
over-production of these innate inflammatory medi-
ators is also associated with anemia [76, 77]. In addi-
tion, persistent macrophage activation is significantly 
greater  in  children  with  complicated  malaria  [78]. 
Excessive release of IFN- and TNF-, along with NO, 
also promote enhanced malarial anemia pathogenesis 
by  contributing  to  bone  marrow  suppression, 
dyserythropoiesis, and erythrophagocytosis [79]. 
IL-1 is a potent endogenous pyrogen that pro-
motes an acute inflammatory response and provides a 
first line of defense against invading pathogens [80]. 
IL-1β and IL-1α synergize with TNF-α to enhance the 
production  of  NO  and  IFN-γ  in  murine  models  of 
malaria [81]. However, high levels of sustained IL-1β 
production  in  inflammatory  diseases  can  induce  a 
number  of  hematological  abnormalities,  including 
anemia [82, 83]. In murine models, administration of 
recombinant  IL-1  can  inhibit  development  of  the 
pre-erythrocytic stages of malaria [84], protect against 
the development of cerebral malaria, and aid in con-
trolling  parasitemia  [85].  Although  several  studies 
have  reported  elevated  peripheral  blood  levels  of 
circulating IL-1β levels in humans with severe malaria 
[86-88], an additional investigation failed to find sig-
nificant changes in IL-1β levels in children with SMA 
[76].  Studies  in  Gambian  children  with  falciparum 
malaria  illustrated  that  IL-1α  and  TNF-α  levels, 
measured upon admission to hospital, were positively 
correlated with venous blood lactate concentrations, 
which  were  approximately  two-fold  higher  in  fatal 
cases  compared  to  survivors  [89].  A  study  by  our 
group investigating the role of IL-1β in the immuno-
pathogenesis  of  SMA  revealed  that  children  with 
SMA had significantly lower levels of IL-1β than par-
asitized children without SMA [90]. In addition, hap-
lotypes of IL-1β promoter polymorphisms that were 
associated with significantly greater risk of develop-
ing  SMA  were  also  associated  with  reduced  IL-1β 
production, whereas those haplotypes associated with 
protection  against  SMA  produced  higher  levels  of 
IL-1β  [90].  Thus,  although  sustained  production  of 
IL-1β  can  promote  anemia  [82,  83],  it  appears  that 
‗high producing‘ haplotypes of IL-1β provide protec-
tion against SMA.  
Elevated levels of IL-6 in the peripheral blood of 
patients with severe P. falciparum malaria was recog-
nized  two  decades  ago  [57].  This  finding  has  since 
been corroborated by a number of studies showing 
elevated IL-6 levels in children with severe malaria 
[75,  76,  88].  An  investigation  in  Gabonese  children 
further demonstrated that peripheral blood mononu-
clear cells (PBMC) are a primary source of increased 
IL-6 production during acute malaria [91]. However, 
studies in murine models illustrate that IL-6 mediates 
protective  immunity  against  the  pre-erythrocytic 
stages of malaria by inducing IL-1β and TNF-α, and 
during the erythrocytic stage of disease by controlling 
parasitemia  through  boosting  of  specific  immuno-
globulin  (Ig)  G  antibodies  [84].  Experimental  infec-
tions  with  P.  falciparum  in  humans  support  these 
findings  in  that  early  IL-6  production  is  associated 
with protective effects [92]. Consistent with the pro-
tective effects of IL-6, lower circulating levels of IL-6 
are associated with hyperparasitemia in Malian chil-
dren  with  falciparum  malaria  [76].  Taken  together, 
these studies support a protective role for IL-6 during 
the early stages of disease by controlling parasitemia. 
However, lack of control over the parasitemia and the 
resulting  progression  towards  severe  disease  may 
explain the association between elevated levels of IL-6 
and enhanced pathophysiology.  
MIF was the first soluble mediator described in 
malaria  [93],  but  has  only  recently  been  more  fully 
explored in the context of malaria pathophysiology by 
our group and a number of others [47, 94-98]. MIF is a 
ubiquitous  cytokine  produced  in  response  to 
pro-inflammatory stimuli by T cells [99, 100], mono-
cytes/macrophages  [101], and  the  anterior  pituitary 
gland [102]. However, unlike most cytokines, MIF is 
constitutively expressed at high levels and stored in 
preformed vesicles, and as such can therefore be rap-
idly  released  without  de novo  gene  expression  [102, 
103]. MIF has potent pro-inflammatory properties that 
are important for both innate and adaptive immune 
responses  to  bacterial  and  parasitic  infections  [100, 
101, 104-106]. Murine models of malaria demonstrat-




hanced  disease  severity  [107]  with  the  MIF  gene 
knock-out mice having less anemia and higher sur-
vival rates following infection with P. chabaudi com-
pared to wild types [108].  
Previous investigations in humans showed that 
MIF  was  elevated  in  intervillous  blood  during  pla-
cental  malaria  [109,  110],  thoracic  blood  vessels  of 
Malawian  children  with  cerebral  malaria  [111], and 
peripheral blood from Zambian children with acute 
malaria [108]. However, results from our laboratory 
were the first to show that elevated MIF protein (in 
circulation) and MIF transcripts (in PBMC) were as-
sociated with less severe forms of falciparum malaria 
[94].  We  subsequently  confirmed  these  results  in  a 
larger study of children (aged <3 years, n=357) with P. 
falciparum-induced malarial anemia in western Kenya 
[47]. In the Kenyan cohort, circulating MIF concentra-
tions declined with increasing severity of anemia and 
significantly correlated with peripheral blood leuko-
cyte  MIF  transcripts.  Interestingly,  MIF  concentra-
tions in peripheral blood were not significantly cor-
related with reticulocyte responses in these children. 
However, multivariate regression modeling, control-
ling for age, gender, and parasitemia, demonstrated 
that elevated levels of PCM were significantly associ-
ated with both SMA and decreased MIF production. 
As  a  complement  to  the  in vivo  studies  in  children 
with  malarial  anemia,  additional  experiments  were 
conducted in PBMC from malaria-naïve individuals 
which  showed  that  phagocytosis  of  PfHz  caused 
dysregulation  in  MIF  production  in  a  apopto-
sis-independent manner [47]. Taken together, inves-
tigations in Gabonese and Kenyan children with ma-
larial  anemia  demonstrate  that  elevated  levels  of 
monocytic  PfHz  are  associated  with  suppression  of 
peripheral  blood  MIF  production  and  enhanced  se-
verity of anemia.  
Another  pro-inflammatory  mediator  that  ap-
pears important in conditioning the pathogenesis of 
SMA  is  IL-23.  Although  largely  unexplored  in  the 
context of SMA, IL-23 is important in mediating the 
development of anemia in autoimmune diseases [112] 
and chronic inflammation [113]. IL-23 is composed of 
two subunits, p19 and p40 [114]. IL-23 shares a num-
ber of common properties with IL-12, including the 
p40 subunit [115], the ability to bind to the IL-12Rβ1 
receptor [116], release from activated myeloid antigen 
presenting cells, promotion of a type 1  immune re-
sponse [114-118], and suppression by both IL-10 [119, 
120] and IL-12p40 homodimers [115, 121]. In addition 
to  the  common  properties  IL-23  shares  with  IL-12, 
there  are  also  distinct  immunological  roles  in  that 
IL-23 acts on activated memory CD4+ T cells, while 
IL-12 promotes Th1 differentiation of naïve CD4+ T 
cells  [114,  122].  Based  on  the  common  and  distinct 
roles of  IL-23 and IL-12, along with the well estab-
lished importance of IL-12 in the pathogenesis of ma-
larial anemia (discussed below in detail), we explored 
the  relationships  among  these  cytokines  in  Kenyan 
children  with  varying  severities  of  malarial  anemia 
[123].  Children  with  malarial  anemia  had  increased 
peripheral blood levels of IL-23 and suppressed IL-12 
relative to healthy controls. Additional experiments in 
cultured  PBMC  revealed  that  hemozoin  caused  a 
sustained induction of IL-23p19 transcripts over 72 h, 
while IL-12p40 and IL-10 transcripts peaked at 24 h, 
and rapidly declined thereafter. This line of investi-
gation suggests that elevated IL-23 levels may be im-
portant  in  the  pathogenesis  of  SMA,  and  that  both 
IL-10 and IL-12 may regulate IL-23 production during 
an infection with P. falciparum.  
Perhaps  one  of  the  most  important  innate  in-
flammatory mediators in the pathogenesis of SMA is 
IL-12, a heterodimeric protein composed of 35 and 40 
kDa subunits, and a prototypical cytokine of the type 
1 immune response [124, 125]. IL-12 is secreted from 
dendritic cells, monocytes, and B-cells in response to 
bacterial  cell  wall  components,  intracellular  patho-
gens,  and  CD40  ligation  [124-126].  IL-12  stimulates 
production of IFN-γ and TNF-α from T-cells and nat-
ural killer (NK) cells [124, 125], thereby further aug-
menting type 1 responses. A number of cytokines and 
chemokines  can  promote  IL-12  [e.g.,  granulocyte 
macrophage-colony stimulating factor (GM-CSF) and 
IFN-γ], while others decrease IL-12 production [e.g., 
IL-4, IL-10, IL-11, IL-13, monocyte chemotactic protein 
(MCP)-1/CCL2, and TGF-β] [125, 126]. As such, the 
overall ability of the innate immune response to gen-
erate  IL-12  is  an  important  event  that  mediates  the 
development of malarial anemia.  
Previous studies in the murine models showed 
that  administration  of  recombinant  IL-12  and  chlo-
roquine ameliorated blood-stage malaria and severe 
anemia,  and  induced  immunity  against  re-infection 
[127].  Additional  murine  malaria  studies  demon-
strated  that  deficient  IL-12  production  is  associated 
with severe anemia and dyserythropoiesis [128]. The 
protective  responses  associated  with  IL-12  against 
blood-stage  malaria  appear  to  be  due  to  increased 
IL-12 production from splenic macrophages and NK 
cells [129, 130] and the ability  of IL-12 to stimulate 
antibody production [131]. Central to the role of IL-12 
in  malaria  is  its  ability  to  act  as  a  hematopoietic 
growth factor [132, 133]. In concert with IL-3, IL-12 
along  with  IL-6,  granulocyte-macrophage  colo-
ny-stimulating factor (GM-CSF), and IL-11 can bolster 
colony formation in dormant hematopoietic progeni-




sistent with this role, our previous studies in children 
with falciparum malaria showed that suppression of 
circulating IL-12 is associated with enhanced malarial 
anemia [77, 134]. Suppression of IL-12 in these chil-
dren was also associated with increasing concentra-
tions of PfHz-containing leukocytes [134]. Additional 
studies from our laboratories demonstrated that chil-
dren with SMA have reduced IL-12 levels through a 
mechanism that involves, at least in part, phagocyto-
sis of PfHz which promotes up-regulation of mono-
cyte-derived IL-10 that, in turn, suppresses IL-12p40 
subunits [135]. 
Anti-inflammatory Mediators 
High levels of anti-inflammatory cytokines, such 
as IL-10, appear to provide protective effects against 
SMA  by  preventing  the  over-production  of 
pro-inflammatory  mediators.  Anti-inflammatory  cy-
tokines are typically produced during the later stages 
of  the  innate  immune  response  to  P.  falciparum  in 
which they down-regulate the potentially pathogenic 
pro-inflammatory  responses  that  are  important  for 
controlling parasitemia [136]. Previous investigations 
show  that  a  low  IL-10  to  TNF-α  ratio  is  associated 
with enhanced severity of malarial anemia [77, 137], 
suggesting  that  the  timing  and  magnitude  of 
pro-inflammatory cytokine production, relative to the 
anti-inflammatory cytokine response, is an important 
determinant of the clinical outcomes of malaria. Alt-
hough  plasma  IL-10  levels  are  elevated  in  Malian 
children with SMA relative to healthy controls [76], 
studies  in  Ghana  showed  that  plasma  IL-10  levels 
were significantly lower in children with SMA com-
pared  to  children  with  cerebral  malaria,  uncompli-
cated  malaria,  or  moderate  malarial  anemia  [138]. 
Additional  studies  have  shown  significant  associa-
tions  between  circulating  IL-10  levels  and  pig-
ment-containing phagocytes in the peripheral blood 
[134], suggesting that malarial pigment plays an im-
portant role in governing the systemic pathology of 
malaria through up-regulation of IL-10 production.  
TGF-β1  is  an  anti-inflammatory  cytokine  (and 
growth factor), which down-regulates the production 
of TNF-α and IL-10 and protects against severe mu-
rine malaria [139]. TGF-β appears to be important in 
malaria pathogenesis [86, 110, 140], and is attributed 
to both positive [141] and negative [141-143] effects on 
erythropoiesis.  Previous  studies  from  our  group 
showed  that  TGF-β1  levels  in  peripheral  blood  are 
significantly reduced in Gabonese children with  se-
vere malaria [77]. However, studies in Burkina Faso 
revealed opposite effects in which severe childhood 
malaria  was  associated  with  increased  plasma  con-
centrations of TGF-β1 [144]. The reason for differing 
results may be due to the differences in malaria en-
demicity since the rural site in Lambaréné, Gabon, has 
a high level of P. falciparum transmission, whereas the 
urban  region  of  Ouagadougou,  Burkina  Faso,  is  a 
mesoendemic area for P. falciparum. Alternatively, it is 
unclear whether or not ‗platelet poor‘ samples were 
used to measure TGF-β1 in the Burkina Faso study, an 
important consideration since platelets contain high 
levels of TGF-β1. A more recent study further sup-
ports the importance of the TGF-β family in malaria 
pathogenesis  by  showing  that  serum  levels  of  the 
soluble form of the TGF-β co-receptor, endoglin (sEng 
or CD105/ TGF-βRIII), was significantly elevated in 
children with severe falciparum malaria [145]. In ad-
dition to TGF-β1, a recent investigation in Angolan 
children  illustrates  that  polymorphic  variability  in 
TGF-β2  conditions  susceptibility  to  the  risk  of  pro-
gressing  to  cerebral  malaria  [146].  It  remains  to  be 
definitively determined if TGF-β2 is also an important 
mediator of SMA pathogenesis.  
 Chemokines 
Chemotactic cytokines, or chemokines, are pri-
marily  known  for  their  chemotactic  properties,  but 
also play important roles in immune activation, hem-
atopoiesis, angiogenesis, and antimicrobial activities 
[147].  Burgmann  et  al.  were  the  first  to  investigate 
chemokines  in  the  context  of  malaria  in  1995  by 
measuring  the  C-C  chemokine,  macrophage  inflam-
matory  protein  (MIP)-1α/CCL3,  and  the  C-X-C 
chemokine, IL-8/CXCL8, in the serum of acutely in-
fected adult patients with P. falciparum infections in 
which they found a positive correlation between par-
asitemia and IL-8/CXCL8 [148]. A subsequent inves-
tigation  revealed  that  Malian  children  with  severe 
malaria  had  ten-fold  higher  concentrations  of 
IL-8/CXCL8 compared to either healthy controls or 
individuals with uncomplicated malaria [76]. IL-8 is 
an  important  neutrophil  activating  chemokine  that 
was also previously shown to be elevated in Thai pa-
tients with severe, non-fatal malaria [149]. Additional 
studies  in  Gabonese  children  and  adults  illustrated 
that higher plasma IL-8 levels were associated with 
acute malaria and a slow  rate of cure after malaria 
chemotherapy [75]. 
It appears that phagocytosis of  PfHz is an im-
portant signal for promoting chemokine production 
and/or suppression. For example, PfHz treatment of a 
bone  marrow-derived  murine  cell  line  increased 
transcript  levels  of  MIP-1α/CCL3,  MIP-1β/CCL4, 
MIP-2/CXCL2, and MCP-1/CCL2 [150]. Concomitant 
studies from our group demonstrated that Gabonese 
children  with  severe  malaria  had  elevated  levels  of 




in circulation) and transcripts (determined in ex vivo 
PBMC)  [151].  Additional  experiments  in  cultured 
PBMC  from  healthy,  malaria-naïve  donors  revealed 
that  PfHz  promoted  increased  MIP-1α/CCL3  and 
MIP-1β/CCL4 production [151]. 
Regulated on activation, normal T-cell expressed 
and secreted (RANTES, CCL5) also appears to play a 
critically important role in the pathogenesis of SMA. 
RANTES  is  secreted  by  a  number  of  cell  types  in-
cluding monocytes, macrophages, fibroblasts, NK and 
T  cells,  and  CD34+  hematopoietic  progenitors 
[152-155].  RANTES  protein  is  sequestered  in  the 
-granules  of  platelets  and  is  released  by  thrombin 
stimulated platelets [156], indicating that RANTES is 
involved  in  both  innate  and  adaptive  immune  re-
sponse. In addition, RANTES stimulates hematopoie-
sis, angiogenesis, cell proliferation, and development 
[157]. An earlier study by our group, which was the 
first to examine  RANTES in the context of malaria, 
demonstrated that RANTES was suppressed in Gab-
onese children with severe malaria, at least in part, 
through PfHz-induced down-regulation of RANTES 
transcripts  in  PBMC  [151].  The  inherent  ability  to 
produce  RANTES/CCL5  also  appears  important  in 
conditioning  susceptibility  to  severe  malaria.  For 
example,  our  investigation  in  Gabon  revealed  that 
healthy  children  with  prior  mild  malaria  produced 
significantly higher RANTES transcripts and protein 
than children with a history of severe malaria [151]. 
These  investigations  were  then  confirmed  in  Kenya 
where  we  showed  that  RANTES  was  significantly 
suppressed in children with SMA [29]. Suppression of 
RANTES in these children was also significantly as-
sociated  with  inefficient  erythropoiesis  and  malar-
ia-induced thrombocytopenia [29]. Subsequent stud-
ies  from  our  laboratories  determined  that  naturally 
acquired PfHz by monocytes promotes suppression of 
RANTES in children with malarial anemia through an 
IL-10-dependent  mechanism  [49].  Taken  together, 
these findings suggest that thrombocytopenia may be 
an important source of reduced RANTES which ap-
pears to contribute to suppression of erythropoiesis in 
children with SMA.  
Growth Factors  
Since a number of growth factors influence the 
erythropoietic cascade, and SMA is clearly a disease 
process in which phagocytosis and lysis of RBCs ne-
cessitates the production of new RBCs to recover from 
anemia, growth factors will clearly emerge as critical 
determinants of clinical outcomes. However, the lit-
erature  is  largely  lacking  with  respect  to  the  im-
portance  of  growth  factors  in  conditioning  the  de-
velopment of SMA. A time-course study in patients 
with  P. falciparum  malaria  in  Thailand  showed  that 
serum levels of granulocyte-colony stimulating factor 
(G-CSF)  were  significantly  elevated  in  individuals 
with complicated disease on day 0 that then declined 
to within the normal range by day 7; G-CSF at day 0 
was  correlated  with  procalcitonin,  parasite  density, 
and  erythropoietin  [158].  Although  not  specifically 
examined in children with SMA, the potential nega-
tive  consequences  associated  with  over-production 
could  certainly  emerge  since  G-CSF  has  a  negative 
impact on erythropoiesis [159-161].  
GM-CSF  is  important  for  promoting  erythro-
poiesis [162] and synergizes with TNF-α to increase 
the killing capabilities of neutrophils on blood-stage 
malaria  parasites  [163].  In  addition,  enhanced  pa-
thology in a murine model of malaria (characterized 
by parasitemia and anemia) was associated with ele-
vated  levels  of  erythropoietin  (EPO),  which  were 
strongly  correlated  with  the  level  of  anemia,  and 
negatively  correlated  with  GM-CSF  concentrations 
[164]. The influence that GM-CSF has on anemia out-
comes  in  children  with  SMA  remains  to  be  deter-
mined.  
 As part of our investigations aimed at identify-
ing genes/gene pathways that could play a role in the 
pathogenesis  of  SMA,  we  utilized  gene  expression 
profiling  from  pooled  fractions  of  human  PBMCs 
stimulated  with  PfHz.  These  experiments  revealed 
that  human  stem  cell  growth  factor  [SCGF,  C-type 
lectin domain family member 11A, (CLEC11A)] was 
up-regulated  following  treatment  with  PfHz  [165]. 
SCGF  is  a  hematopoietic  growth  factor,  expressed 
primarily by myeloid cells and fibroblasts that possess 
burst-promoting  activity  for  human  bone  marrow 
erythroid  progenitors  [166].  Human  SCGF-α  is  a 
323-amino acid protein, while SCGF-β is a 245-amino 
acid  protein  that  results  from  cleavage  of  the  con-
served carbohydrate domain [167]. After determining 
the in vitro kinetics of SCGF expression in response to 
PfHz, we then examined circulating SCGF levels  in 
Kenyan children with malarial anemia. SCGF levels in 
circulation  and  in  cultured  peripheral  blood  were 
significantly suppressed in children with SMA, with 
circulating  SCGF  levels  being  positively  correlated 
with Hb concentration and the RPI [165]. SCGF was 
significantly  lower  in  children  with  a  suppressed 
erythropoietic  response  and  in  children  with  high 
levels  of  naturally  acquired  monocytic  PfHz  [165]. 
Our  additional  investigation  showed  that  a  novel 
SCGF  promoter  variant  (–539C/T,  rs7246355)  was 
significantly  associated  with  susceptibility  to  SMA 
and reduced erythropoietic responses with the ‗high 
producing‘ TT genotype protecting against develop-




parasitized  children  [168].  Taken  together,  these  re-
sults illustrate that SCGF is an important mediator of 
SMA  pathogenesis  that  may  offer  the  potential  for 
immunotherapy in future clinical trials.  
Effector Molecules 
As  described  above,  the  clinical  outcomes  of 
malaria  are  largely  conditioned  by  the  relative  ex-
pression  of  inflammatory  mediators.  The  relative 
timing and magnitude of pro- and anti-inflammatory 
cytokines,  chemokines,  and  growth  factors  released 
into the inflammatory milieu have direct actions on 
the  cellular  response  as  well  as  the  ‗down-stream‘ 
effector  molecules  that  ultimately  get  produced.  As 
such,  effector  molecules  play  a  critical  role  in  the 
pathogenesis of SMA. One important effector mole-
cule in malaria is the toxic free radical, NO. NO and 
equimolar  amounts  of  L-citrulline  are  generated  by 
catalysis  of  L-arginine  by  the  NO  synthases  (NOS) 
[169]. In the context of an acute inflammatory disease, 
such  as  malaria,  much  of  the  NO  produced  comes 
from  the  cytokine  inducible  isoform,  nitric  oxide 
synthase  type  2  [NOS2  or  inducible  NO  synthase 
(iNOS)]  present  in  monocytes,  macrophages,  and 
neutrophils [170]. In general, pro-inflammatory cyto-
kines  (e.g.  IL-12,  IFN-γ,  and  TNF-α)  increase 
NOS2-generated  NO  production,  whereas  an-
ti-inflammatory  cytokines  (e.g.  IL-10  and  TGF-β) 
down-regulate  NOS2  expression  (for  review  see 
[171]). Although the role of NO in the pathogenesis of 
malaria  has  been  debated  for  nearly  a  decade,  it  is 
apparent that NO is both protective and pathogenic. 
For example,  NO  is protective in that it has potent 
parasiticidal properties against P. falciparum [65] and 
can thereby limit parasitemia [172]. A protective effect 
is  also  illustrated  by  our  previous  investigation 
showing  that  healthy,  malaria-exposed  Gabonese 
children with a history of mild malaria have signifi-
cantly higher levels of ex vivo PBMC NO production 
and NOS enzymatic activity than their age-matched 
cohort with a history of severe malaria [173]. Howev-
er, our follow-up investigation in the same population 
revealed  that  ex  vivo  and  in  vitro  NOS  activity  in 
PBMCs was significantly higher in children with ma-
larial anemia in which there was an inverse associa-
tion between NOS enzyme activity and hemoglobin 
levels  [174].  Additional  experiments  confirmed  that 
PfHz  was  an  important  source  of  NOS2  transcripts 
and NO production [174]. Thus, although NO serves 
an  important  role  in  controlling  parasitemia,  it  is 
likely  that  sustained,  high  levels  of  NO  production 
also promotes anemia. This premise is supported by 
the fact that generation of NO during a malarial in-
fection  can  promote  severe  anemia  through  bone 
marrow  suppression,  dyserythropoiesis,  and 
erythrophagocytosis (for review see [79]).  
In addition to NO, reactive oxygen species (ROS) 
also appear to be both protective and pathogenic in 
human  malaria.  High  levels  of  oxygen  radical  pro-
duction are associated with accelerated clearance of 
parasitemia  in  Gabonese  children  with  falciparum 
malaria  [175].  In  addition,  ROS  are  important  for 
controlling  peripheral  parasitemia  in  children  with 
severe  malaria  [176].  A  pathogenic  role  for  ROS  is 
illustrated  by  a  study  in  Kenyan  children  showing 
that ROS cause damage to the erythrocytic membrane 
(demonstrated by measurement of α-tocopherol and 
polyunsaturated  fatty  acid  levels  in  the  erythrocyte 
membrane)  [177].  A  recent  investigation  in  Indian 
children (<15 years of age) infected with P. falciparum 
(in which the primary disease manifestation of severe 
malaria was SMA) revealed that severe malaria cases 
had significantly elevated markers of oxidant stress, 
including malondialdehyde, protein carbonyl, nitrite, 
ascorbic  acid,  and  copper  levels  [178].  Although  a 
wealth of data exists on the topic of free radicals in 
malaria, such a discussion is beyond the scope of this 
review.  However,  studies  outlined  here  highlight 
both the protective and pathogenic roles of reactive 
nitrogen and oxygen intermediates. 
Prostaglandin  (PG)E2  is  synthesized  from  ara-
chidonic  acid  (AA)  through  the  catalytic  activity  of 
cyclooxygenase (COX) enzymes also known as pros-
taglandin-H2  (PGH2)  synthase,  which  exists  in  two 
isozymes: COX-1 (PGH synthase-1) and COX-2 (PGH 
synthase-2). Constitutively expressed COX-1 catalyses 
immediate  biosynthesis  of  PGE2  and  other  pros-
tanoids  involved  in  physiological  homeostasis, 
whereas inducible COX-2 catalyses delayed formation 
of  PGE2 and  prostanoids  involved  in  regulating  the 
inflammatory  response  and  immunity  to  invading 
pathogens [179]. Formation of PGH2, the committed 
step in prostanoid biosynthesis, promotes generation 
of primary prostanoids [i.e., PGE2, PGH2, thrombox-
ane A2, PGD2, PGF2α, and prostacyclin (PGI2) through 
the action of respective terminal prostanoid synthases 
[179]. Our previous study illustrates that intervillous 
blood mononuclear cell (IVBMC) PGE2 production is 
reduced in parasitemic women of all gravidae due, at 
least  in  part,  to  acquisition  of  intraleukocytic  PfHz 
[180]. Additional studies from our group have shown 
that plasma bicyclo-PGE2 (a stable end metabolite of 
PGE2) and ex vivo PBMC COX-2 gene expression are 
significantly reduced in Gabonese children with  se-
vere malaria [181]. Studies in Tanzanian children also 
showed  that  suppression  of  systemic  bicyclo-PGE2 
production  (measured  in  urine)  was  suppressed  in 




vitro  experiments  in  our  laboratories  revealed  that 
reduced  PGE2 biosynthesis  in  children  with  falcipa-
rum malaria was largely due to inhibition of de novo 
COX-2 transcripts following phagocytosis of PfHz by 
monocytes [183, 184]. Further investigation of the role 
of prostaglandins in childhood malaria showed that 
suppression  of  PGE2  by  PfHz  and  commonly  used 
antipyretics  to  treat  the  malarial  fever  promoted 
over-production of TNF-, an event associated with 
enhanced malaria pathogenesis [183, 184].  
12. In vitro Models for Investigating Sup-
pression of Erythropoiesis in Malarial 
Anemia 
In vitro studies have shown that PfHz directly (or 
in synergy with TNF-α) inhibits erythroid cell devel-
opment  [46].  In  addition  to  inducing  erythropoie-
sis-inhibiting cytokines, PfHz has direct effects on the 
erythropoietic  cascade  through  its  ability  to  cause 
apoptosis  of  erythroid  precursor  cells  via  oxidative 
stress [185]. We recently developed an in vitro model 
of  erythropoiesis  using  CD34+  stem  cells  isolated 
from  human  peripheral  blood  to  investigate  the  ef-
fects of inflammatory mediators on erythroid devel-
opment  [186].  This  model  showed  that  PfHz  only 
slightly  suppressed  erythroid  cell  proliferation  and 
maturation, marked by decreased expression of gly-
cophorin  A  (GPA)  [186].  However,  the  addition  of 
PfHz-stimulated  PBMC-conditioned  media 
(PfHz-CM), recombinant TNF-α, and NO donors sig-
nificantly inhibited erythroid cell proliferation [186]. 
The decreased proliferation witnessed in cells treated 
with  PfHz-CM  and  NO  was  accompanied  by  in-
creased  apoptosis  of  erythropoietin-stimulated 
CD34+ cells [186]. Interestingly, the addition of NO 
donors significantly inhibited erythroid cell matura-
tion, whereas TNF-α failed to impact on maturation. 
These  results  demonstrate  that  PfHz  suppresses 
erythropoiesis  by  acting  directly  on  erythroid  cells, 
and  to  a  greater  extent,  through  indirect  effects  in 
which phagocytosis of PfHz generates inflammatory 
mediators  which  have  adverse  effects  on  erythroid 
development. 
13. Conclusion 
Studies outlined here support a model in which 
the pathogenesis of SMA is largely driven by dysreg-
ulation  in  pro-  and  anti-inflammatory  cytokines, 
chemokines, growth factors, and effector molecules. 
Altered patterns of these innate inflammatory medi-
ators is due, at least in part, to the phagocytosis of 
PfHz by monocytes, resident macrophages (including 
those in bone marrow), and neutrophils. The mecha-
nisms that lead to the profoundly low Hb concentra-
tions witnessed in children with SMA are due to he-
molysis  and  phagocytosis  of  parasitized  and 
non-parasitized RBCs, and to a large extent, by sup-
pression  of  erythropoiesis  that  is  driven  by 
PfHz-generated dysregulation in innate inflammatory 
mediators. While it is clear that overcoming the global 
burden  of  SMA  will  continue  to  present  a  serious 
challenge,  it  is  our  hope  that  gaining  an  improved 
understanding of pathogenic events that cause sup-
pression of erythropoiesis, particularly dysregulation 
in innate immunity, may offer future treatment strat-
egies to combat the unacceptable rates of morbidity 
and mortality associated with SMA.  
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